Urinary oxalic acid (oxaluric aciduria)
Oxalate Metabolism
Urinary oxalate comes from two distinct sources: intestinal absorption of dietary oxalates and endogenous production in the liver. In a healthy individual on a standard diet, approximately 40 to 50% of urinary oxalate is of dietary origin and 50 to 60% is of endogenous origin. However, this distribution varies greatly depending on diet and the condition of the intestinal mucosa.
Endogenous hepatic production of oxalate mainly results from the catabolism of two precursors: glycine (via glyoxylate oxidase) and ascorbic acid (vitamin C), whose oxidation produces oxalate. Glyoxylate is the common intermediate precursor, transformed into oxalate by lactate dehydrogenase and glycolate oxidase. In hereditary primary hyperoxalurias, specific enzymatic deficits in this metabolic pathway lead to massive endogenous overproduction.
At the intestinal level, free dietary oxalate is absorbed mainly in the colon by an active transport mechanism involving the anion exchanger SLC26A6. The binding of oxalate to dietary calcium in the intestinal lumen forms an insoluble (calcium oxalate) salt, which is not absorbable. This explains why sufficient calcium intake during meals reduces intestinal oxalate absorption and oxaluria. Gut flora, notably Oxalobacter formigenes, degrades part of the luminal oxalate, reducing its availability for absorption; the disappearance of this commensal after antibiotic therapy can contribute to moderate hyperoxaluria.
Oxaluria reference values
| Population | Normal values (24-hour urine) | Hyperoxaluria cutoff |
|---|---|---|
| Adult (male) | 10 to 40 mg/24 h (110 to 445 µmol/24 h) | Greater than 45 mg/24 h (500 µmol/24 h) |
| Adult (female) | 8 to 32 mg/24 h (90 to 355 µmol/24 h) | Greater than 40 mg/24 h (445 µmol/24 h) |
| Child (weight-adjusted) | Less than 0.5 mmol/1.73 m² of body surface area per 24 hours | Greater than 0.5 mmol/1.73 m²/24 h; specific pediatric normal values by age and body surface area |
| Mild to moderate hyperoxaluria | 40 to 80 mg/24 h | Most often associated with enteric or dietary hyperoxaluria; increased lithiasis risk but progressive evolution |
| Severe hyperoxaluria | 80 to 200 mg/24 hours | Workup for hereditary primary hyperoxaluria or severe intestinal malabsorption; specialized etiological investigation is imperative |
| Massive hyperoxaluria | Greater than 200 mg/24 h | Primary hyperoxaluria type 1 (alanine-glyoxylate aminotransferase deficiency); high risk of systemic oxalosis and renal failure |
Classification of hyperoxalurias
| Type | Mechanism | Oxaluria | Clinical context |
|---|---|---|---|
| Dietary hyperoxaluria | Excessive intake of oxalate-rich foods (spinach, beets, nuts, chocolate, rhubarb, black tea) or precursors (high-dose vitamin C greater than 1 g/day); increased intestinal absorption | Mild to moderate; typically 40 to 60 mg/24 h; normalizes with dietary restriction | Very common; the first cause to consider and correct before any in-depth examination; diet to investigate in detail |
| Enteric hyperoxaluria | Intestinal fat malabsorption with saponification of luminal calcium by unabsorbed fatty acids; calcium unavailable to bind oxalate; colonic hyperabsorption of free oxalate; disruption of intestinal flora reducing bacterial degradation of oxalate | Moderate to severe; 60 to 150 mg/24 h; directly correlated with the severity of malabsorption | Ileal Crohn's disease, extended ileal resection, fat malabsorption (chronic pancreatitis, celiac disease, gastric bypass, sleeve or bypass bariatric surgery); major cause of secondary hyperoxaluria in adults |
| Primary hyperoxaluria type 1 (PH1) | Hepatic alanine-glyoxylate aminotransferase (AGXT) deficiency; accumulation of glyoxylate converted to oxalate; massive endogenous hepatic overproduction; autosomal recessive inheritance; gene AGXT chromosome 2q36 | Typically above 100 mg/24h, often above 200 mg/24h; very high oxalate/creatinine ratio | Most frequent and severe form of primary hyperoxaluria; progressive oxalosis nephropathy with possible end-stage renal disease from childhood; systemic oxalosis (bone, cardiac, ocular, skin deposits); treatment with pyridoxine (responders), lumasiran (hepatic siRNA), and combined liver-kidney transplantation |
| Primary hyperoxaluria type 2 (PH2) | Glyoxylate reductase/hydroxypyruvate reductase (GRHPR) deficiency; gene GRHPR (chromosome 9p11); overproduction of oxalate and L-glycerate; autosomal recessive | Moderate to severe; associated high glyceraturia (urinary L-glycerate); less severe than HP1 | Recurrent childhood lithiasis; slower progression to renal failure than HP1; no response to pyridoxine; lumasiran under study |
| Primary hyperoxaluria type 3 (PH3) | 4-hydroxy-2-oxoglutarate aldolase (HOGA1) deficiency; gene HOGA1 (chromosome 10q24); autosomal recessive; indirect mechanism via accumulation of a glyoxylate reductase inhibitor | Moderate; often less than 100 mg/24 h; elevated urinary 2-keto-glutarate and hydroxy-glutarate levels | The most benign form of primary hyperoxaluria; recurrent calcium oxalate lithiasis; rare renal insufficiency; sometimes spontaneous improvement with age |
| Idiopathic hyperoxaluria | Intestinal hyperabsorption of oxalate with no identified cause; possibly related to increased intestinal permeability or variation in microbial flora | Mild to moderate; 40 to 80 mg/24h; no documented digestive abnormalities | Exclusion diagnosis after ruling out dietary, enteric, and hereditary causes; treatment: oxalate-restricted diet, abundant hydration, calcium supplementation with meals |
High oxalate foods and impact on oxaluria
| Category | Foods with very high oxalate content | Moderately nutritious foods |
|---|---|---|
| Vegetables and plants | Spinach (750 mg/100 g), Swiss chard, rhubarb (500 mg/100 g), raw beet, sorrel, parsley | Green beans, leeks, zucchini, sweet potato, celery, asparagus |
| Nuts and seeds | Cashew nuts, almonds (460 mg/100 g), walnuts (80 mg/100 g), sesame seeds, peanuts | Hazelnuts, pistachios, sunflower seeds |
| Drinks | Black tea infused (14 mg/240 ml), green tea, beet juice, spinach juice | Coffee (regular), beer, apple juice, soy drinks |
| Cereals and starches | Wheat bread, whole wheat flour, rolled oats | White bread, white rice, regular pasta |
| Other | Dark chocolate and cocoa (500 mg/100 g), carob, soy miso | Milk chocolate (calcium-diluted), red fruit jams |
| Supplements | Vitamin C at a dose exceeding 1 g/day (metabolic conversion to oxalate accounting for 30 to 50% of the dose) | Vitamin C below 500 mg/day: minimal impact on oxaluria |
Oxaluria Dosage Indications
- Comprehensive metabolic evaluation of kidney stones, particularly in cases of a first stone in a young person (under 40 years old), recurrent stones (at least two episodes), bilateral stones, multiple simultaneous stones, or a family history of calcium oxalate stones
- Suspicion of hereditary primary hyperoxaluria in cases of calcium oxalate stones starting in childhood or young adulthood, oxalosis, or unexplained nephrocalcinosis.
- Metabolic monitoring of ileal Crohn's disease, surgical ileal resection, or significant intestinal malabsorption, with evaluation of associated oxalocalcic risk
- Follow-up after bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy), a procedure known to increase enteric hyperoxaluria and the risk of calcium oxalate stones.
- Evaluation of the impact of high-dose vitamin C supplementation on oxaluria before continuing such supplementation in a kidney stone patient
- Pre-kidney transplant assessment in a patient with chronic kidney failure of indeterminate etiology, to exclude systemic oxalosis (primary hyperoxaluria) contraindicating isolated kidney transplantation
- Therapeutic monitoring of the effectiveness of dietary measures, calcium supplementation with meals, or drug treatment (pyridoxine, lumasiran) on the reduction of oxaluria
Collection modalities and pre-analytical factors
The reliability of 24-hour oxaluria directly depends on the quality of collection and adherence to pre-analytical conditions. Oxalate is unstable in urine and subject to rapid bacterial degradation, as well as oxidation of ascorbic acid to oxalate in vitro, which can falsely elevate results.
| Parameter | Practical recommendation | Reason |
|---|---|---|
| Acidification of the collection | Collection in a container with hydrochloric acid (HCl 6N) or ascorbic acid provided by the laboratory; maintaining a urinary pH below 2 | Prevention of bacterial degradation of oxalate and precipitation of calcium oxalate in the container, which would underestimate the result |
| Cold storage | Collection kept in the refrigerator (4°C) for the entire duration of the collection | Slowing of bacterial growth and oxidation reactions |
| Feeding during collection | Usual diet maintained without modification; avoid a drastic oxalate restriction that would underestimate usual oxaluria | Obtain a representative measure of the patient's actual metabolic status |
| Vitamin C and medications | Discontinue any vitamin C supplementation exceeding 500 mg/day at least 24 hours prior to collection; inform the laboratory of any medications that may interfere. | Ascorbic acid is oxidized in vitro to oxalate, artificially increasing measured oxaluria. |
| Concurrent creatininuria | Always measure the 24-hour urine creatinine on the same collection. | Completeness check of the collection; an incomplete collection would underestimate oxaluria. |
| Hydration | Usual hydration during collection; do not over-hydrate unusually | Exceptionally abundant diuresis would dilute the oxalate without reflecting the usual situation |
Interpretation in the context of a complete lithiasic assessment
Oxaluria should not be interpreted in isolation but as part of a complete metabolic urinary assessment, combining the main lithogenic and protective factors. Urinary supersaturation of calcium oxalate, a key parameter for crystallization risk, depends not only on oxaluria but also on calciuria, 24-hour diuresis, urinary pH, citraturia (a natural crystallization inhibitor), and magnesuria.
| Associated parameter | Normal range (adult) | Interaction with oxaluria |
|---|---|---|
| Urine calcium (24-hour urine calcium) | Man: less than 300 mg/24 h; woman: less than 250 mg/24 h | Hypercalciuria associated with high oxaluria synergistically multiplies the risk of lithiasis; calcium oxalate supersaturation increases proportionally to the product [Ca²+] x [Ox²-] |
| Urine citrate (24h urine citrate) | Male: greater than 450 mg/24 hr; female: greater than 550 mg/24 hr | Citrate is the main inhibitor of calcium oxalate crystallization; hypocitraturia worsens the lithiatic risk of hyperoxaluria; frequent association in intestinal malabsorption (metabolic acidosis) |
| 24-hour urine output | Greater than 2 liters per 24 hours (lithiasis recommendation) | Insufficient diuresis concentrates urinary oxalate and worsens supersaturation; increasing fluid intake is the most effective measure to reduce the risk of crystallization, regardless of the level of oxaluria. |
| Urine pH | 5.5 to 6.5 (variable throughout the day) | Calcium oxalate crystallizes independently of urinary pH (unlike uric acid); however, a very low pH favors mixed oxalocalcic and uric lithiasis. |
| Urinomagnesemia (24-hour urinary magnesium) | 60 to 120 mg/24h | Magnesium forms soluble complexes with oxalate, reducing the free fraction available for crystallization; hypomagnesuria (associated with malabsorption) worsens the lithiasic risk. |
| Uricosuria (24-hr urinary uric acid) | Less than 800 mg/24 h (male); less than 700 mg/24 h (female) | Hyperuricosuria promotes heterogeneous crystallization of calcium oxalate by epitaxy on urate crystals; a frequent association in mixed calculi. |
Therapeutic approach according to the type of hyperoxaluria
| Type of hyperoxaluria | First-line measures | Specific treatments |
|---|---|---|
| Dietary hyperoxaluria | Restriction of foods very high in oxalate (spinach, rhubarb, nuts, chocolate), cessation of vitamin C supplementation above 500 mg/day, increase in dietary calcium intake with meals (800 to 1,200 mg/day of calcium) | Supplementation with calcium citrate with meals (500 mg elemental calcium with each main meal) to chelate luminal oxalate; abundant hydration aiming for diuresis greater than 2.5 L/24 h; follow-up of oxaluria at 3 months to assess response |
| Enteric hyperoxaluria | Treatment of underlying malabsorption; low-fat diet to reduce calcium saponification; calcium supplementation with meals (calcium citrate or carbonate depending on gastric pH) | Cholestyramine (bile acid and oxalate binding resin in the digestive tract); magnesium supplementation; potassium citrate for associated hypocitraturia; probiotics containing Oxalobacter formigenes under study |
| Primary hyperoxaluria type 1 | Massive fluid replacement (3 to 4 L/24 h), potassium citrate or sodium citrate to inhibit crystallization, pyridoxine (vitamin B6, 5 to 10 mg/kg/day) for responsive patients (approximately 30% of HP1 cases) | Lumasiran (Oxlumo): a small interfering RNA (siRNA) targeting the mRNA of hepatic glycolate oxidase, approved by Health Canada; reduces oxaluria by 60–80%; combined liver-kidney transplantation in cases of end-stage renal disease (kidney transplantation alone is contraindicated because the graft will rapidly become oxalated) |
| Primary hyperoxaluria types 2 and 3 | Abundant hydration, potassium citrate; moderate restriction of dietary oxalate; regular renal monitoring | Lumasiran is being studied for PH2; nedosiran bialanate and other gene therapies are under evaluation; kidney transplantation is the only option for PH2 and PH3 (without primary liver involvement); follow-up in a specialized center for hereditary metabolic diseases. |
Consult at Clinique Omicron
Clinique Omicron's doctors, at their service points in Quebec, provide a comprehensive metabolic assessment for patients with kidney stones. This includes a 24-hour oxaluria measurement as part of a tailored prescription and a properly supervised collection. For recurrent kidney stones or a first stone in a young patient, our practitioners initiate a complete metabolic urinary assessment, including oxaluria, calciuria, citraturia, uricosuria, magnesuria, and diuresis measurement, to identify the predominant mechanism and personalized preventive measures. In cases of significant hyperoxaluria, coordination with nephrology or a hereditary metabolic disease unit is arranged for complex forms. For patients who have undergone bariatric surgery or suffer from ileal Crohn's disease, our teams provide specific metabolic monitoring, including regular screening for enteric hyperoxaluria. Book an appointment at one of our service points on the South Shore or at one of our branches in Quebec. Teleconsultation is available for the review of biological assessments and initial diagnostic guidance.
The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.